Navelbine (Vinorelbine Tartrate)

Vinorelbine Tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral formulation for oral use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine Tartrate is a Vinca alkaloid used in oncology to inhibit cell division in solid tumours. - Non‑small cell lung cancer: improves disease control and overall survival in eligible adults. - Metastatic breast cancer: provides tumour response and delays disease progression after prior therapy. - Other solid tumours (off‑label): may be considered to manage tumour growth when standard options are exhausted.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Neutropenia: reduced white blood cell count. - Constipation: decreased bowel movements. - Fatigue: generalized tiredness. - Alopecia: hair thinning or loss.

Serious or Rare Side Effects: - Severe neutropenia with infection risk. - Pulmonary toxicity, including interstitial pneumonitis. - Peripheral neuropathy causing tingling or numbness. - Severe allergic reactions such as anaphylaxis. - Cardiac arrhythmias or QT prolongation. - Hepatic dysfunction with elevated liver enzymes.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check hepatic enzymes prior to and during treatment. - Evaluate pulmonary status: avoid in patients with pre‑existing severe lung disease. - Avoid use in active severe infection: postpone dosing until infection resolves. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Vinorelbine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase toxicity. - Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging drugs (e.g., macrolide antibiotics): monitor cardiac rhythm. - Anticoagulants (e.g., warfarin): observe for altered coagulation parameters.